These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

424 related articles for article (PubMed ID: 27796912)

  • 21. Single-inhaler fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol plus umeclidinium using two inhalers for chronic obstructive pulmonary disease: a randomized non-inferiority study.
    Bremner PR; Birk R; Brealey N; Ismaila AS; Zhu CQ; Lipson DA
    Respir Res; 2018 Jan; 19(1):19. PubMed ID: 29370819
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Umeclidinium/Vilanterol Versus Tiotropium/Olodaterol in Maintenance-Naïve Patients with Moderate Symptomatic Chronic Obstructive Pulmonary Disease: A Post Hoc Analysis.
    Alcázar Navarrete B; Boucot I; Naya I; Tombs L; Lipson DA; Compton C; Sousa AR; Feldman G
    Pulm Ther; 2018 Dec; 4(2):171-183. PubMed ID: 32026389
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The IMPACT Study - Single Inhaler Triple Therapy (FF/UMEC/VI) Versus FF/VI And UMEC/VI In Patients With COPD: Efficacy And Safety In A Japanese Population.
    Kato M; Tomii K; Hashimoto K; Nezu Y; Ishii T; Jones CE; Kilbride S; Gross AS; Clifton CS; Lipson DA
    Int J Chron Obstruct Pulmon Dis; 2019; 14():2849-2861. PubMed ID: 31839705
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-Analysis.
    Ismaila AS; Haeussler K; Czira A; Youn JH; Malmenäs M; Risebrough NA; Agarwal J; Nassim M; Sharma R; Compton C; Vogelmeier CF; Han MK; Halpin DMG
    Adv Ther; 2022 Sep; 39(9):3957-3978. PubMed ID: 35849317
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dual Bronchodilation with Indacaterol Maleate/Glycopyrronium Bromide Compared with Umeclidinium Bromide/Vilanterol in Patients with Moderate-to-Severe COPD: Results from Two Randomized, Controlled, Cross-over Studies.
    Kerwin E; Ferguson GT; Sanjar S; Goodin T; Yadao A; Fogel R; Maitra S; Sen B; Ayers T; Banerji D
    Lung; 2017 Dec; 195(6):739-747. PubMed ID: 28993871
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial.
    Lee LA; Bailes Z; Barnes N; Boulet LP; Edwards D; Fowler A; Hanania NA; Kerstjens HAM; Kerwin E; Nathan R; Oppenheimer J; Papi A; Pascoe S; Brusselle G; Peachey G; Sule N; Tabberer M; Pavord ID
    Lancet Respir Med; 2021 Jan; 9(1):69-84. PubMed ID: 32918892
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of rescue medication use and medication adherence receiving umeclidinium/vilanterol versus tiotropium bromide/olodaterol.
    Moretz C; Bengtson LG; Sharpsten L; Koep E; Le L; Tong J; Stanford RH; Hahn B; Ray R
    Int J Chron Obstruct Pulmon Dis; 2019; 14():2047-2060. PubMed ID: 31564852
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus dual therapy in current and former smokers with COPD: IMPACT trial post hoc analysis.
    Bardsley S; Criner GJ; Halpin DMG; Han MK; Hanania NA; Hill D; Lange P; Lipson DA; Martinez FJ; Midwinter D; Siler TM; Singh D; Wise RA; van Zyl-Smit RN; Berkman N
    Respir Med; 2022 Dec; 205():107040. PubMed ID: 36470149
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of Rescue Medication Prescriptions in Patients with Chronic Obstructive Pulmonary Disease Receiving Umeclidinium/Vilanterol versus Tiotropium Bromide/Olodaterol in Routine Clinical Practice in England.
    Requena G; Czira A; Banks V; Wood R; Tritton T; Castillo CM; Yeap J; Wild R; Compton C; Rothnie KJ; Herth F; Quint JK; Ismaila AS
    Int J Chron Obstruct Pulmon Dis; 2023; 18():1431-1444. PubMed ID: 37465818
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Once-Daily Triple Therapy in Patients with COPD: Patient-Reported Symptoms and Quality of Life.
    Tabberer M; Lomas DA; Birk R; Brealey N; Zhu CQ; Pascoe S; Locantore N; Lipson DA
    Adv Ther; 2018 Jan; 35(1):56-71. PubMed ID: 29313286
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 24-Hour Serial Spirometric Assessment of Once-Daily Fluticasone Furoate/Umeclidinium/Vilanterol Versus Twice-Daily Budesonide/Formoterol in Patients with COPD: Analysis of the FULFIL Study.
    Lipson DA; Birk R; Brealey N; Zhu CQ
    Adv Ther; 2020 Dec; 37(12):4894-4909. PubMed ID: 33011864
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Early and sustained symptom improvement with umeclidinium/vilanterol
    Kerwin EM; Boucot IH; Vogelmeier CF; Maltais F; Naya IP; Tombs L; Jones PW; Lipson DA; Keeley T; Bjermer L
    Ther Adv Respir Dis; 2020; 14():1753466620926949. PubMed ID: 32462979
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preventing Clinically Important Deterioration of COPD with Addition of Umeclidinium to Inhaled Corticosteroid/Long-Acting β
    Naya IP; Tombs L; Lipson DA; Compton C
    Adv Ther; 2018 Oct; 35(10):1626-1638. PubMed ID: 30191464
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of once-daily, single-inhaler fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol in Japanese patients with inadequately controlled asthma: the CAPTAIN study.
    Nakamura Y; Hozawa S; Sagara H; Ohbayashi H; Lee LA; Crawford J; Tamaoki J; Nishi T; Fowler A
    Curr Med Res Opin; 2021 Sep; 37(9):1657-1665. PubMed ID: 34162298
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 28-Day safety and tolerability of umeclidinium in combination with vilanterol in COPD: a randomized placebo-controlled trial.
    Feldman G; Walker RR; Brooks J; Mehta R; Crater G
    Pulm Pharmacol Ther; 2012 Dec; 25(6):465-71. PubMed ID: 22955035
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inpatient Admissions and Re-Admissions in Medicare Beneficiaries Initiating Umeclidinium/Vilanterol or Tiotropium Therapy.
    Bogart M; Leung GY; Cyhaniuk A; DiRocco K
    Int J Chron Obstruct Pulmon Dis; 2024; 19():439-450. PubMed ID: 38374817
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and Safety of Umeclidinium/Vilanterol in Current and Former Smokers with COPD: A Prespecified Analysis of The EMAX Trial.
    Bjermer LH; Boucot IH; Vogelmeier CF; Maltais F; Jones PW; Tombs L; Compton C; Lipson DA; Kerwin EM
    Adv Ther; 2021 Sep; 38(9):4815-4835. PubMed ID: 34347255
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of once-daily inhaled umeclidinium/vilanterol in Asian patients with COPD: results from a randomized, placebo-controlled study.
    Zheng J; Zhong N; Newlands A; Church A; Goh AH
    Int J Chron Obstruct Pulmon Dis; 2015; 10():1753-67. PubMed ID: 26366068
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Single inhaler triple therapy (FF/UMEC/VI) versus FF/VI and UMEC/VI in patients with COPD: subgroup analysis of the China cohort in the IMPACT trial.
    Zheng J; Zhong N; Wang C; Wei LP; Zhou XD; Zhao L; Dong Yuan Y; He B; Wu B; Du X; Song J; Lipson DA
    Curr Med Res Opin; 2021 Jan; 37(1):145-155. PubMed ID: 33124900
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Umeclidinium/vilanterol versus fluticasone propionate/salmeterol in COPD: a randomised trial.
    Singh D; Worsley S; Zhu CQ; Hardaker L; Church A
    BMC Pulm Med; 2015 Aug; 15():91. PubMed ID: 26286141
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.